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Abstract
Active surveillance (AS) is increasingly recognized as a reasonable option for men with low-risk, 
localized prostate cancer, yet few men who might benefit from conservative management receive 
it. We examined the acceptability of normative messages about AS as a management option for 
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patients with low-risk prostate cancer. Men with a diagnosis of localized prostate cancer who were 
recruited through prostate cancer support organizations completed a web-based survey (N=331). 
They rated messages about AS for believability, accuracy, and importance for men to hear when 
making treatment decisions. The message “you don’t have to panic…you have time to think about 
your options” was perceived as believable, accurate, and important by over 80% of the survivors. 
In contrast, messages about trust in the AS protocol and “knowing in plenty of time” if treatment 
is needed were rated as accurate by only about 36% of respondents. For AS to be viewed as a 
reasonable alternative, men will need reassurance that following an AS protocol is likely to allow 
time for curative treatment if the cancer progresses.
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Introduction
At the heart of the current prostate cancer screening controversy is the accompanying and 
significant risk of overdiagnosis and overtreatment that can prove costly to both the patient’s 
quality of life and the healthcare system (Sandhu & Andriole, 2012). Recently, the National 
Cancer Institute in the United States has argued that physicians and patients need to 
recognize that overdiagnosis is a common result of cancer screening (Esserman, Thompson, 
& Reid, 2013). For men at low risk of dying from prostate cancer, treatment is not likely to 
improve prognosis and may instead leave these patients with significant adverse effects 
(e.g., impotence and incontinence) that negatively affect quality of life (Carter, 2012). 
According to current UK National Institute for Health and Clinical Excellence (NICE) 
guidelines (issued in 2008), active surveillance (AS) should be the preferred treatment for 
low-risk patients (Branney, White, Jain, Hiley, & Flowers, 2009). Nevertheless, active 
treatment for low-risk patients has increased in recent years (Jacobs et al., 2013). In the US, 
fewer than one in five patients with low-risk prostate cancer select AS (Cooperberg, 
Broering, & Carroll, 2010), suggesting a missed opportunity for conservative management 
and reducing treatment-related harms (Carter, 2012).
Because of the discrepancy between guidelines and treatment choice for patients with low-
risk prostate cancer, we studied the effect of normative messages to address underutilization 
of AS. Normative messages effectively promote desirable behaviors through expression of 
the behavior as a social norm, an expectation or rule that governs behavior within a group 
(Bicchieri & Muldoon). Psychologists, as well as other researchers, have determined that 
norms are powerful influences on decision making and behavior. For example, in one study, 
researchers tested whether descriptive norm information (e.g., the proportion of other people 
choosing a particular treatment) would influence people’s hypothetical choices about cancer 
treatment and found that patients had more interest in chemotherapy when the norm 
information suggested that it was popular (Zikmund-Fisher, Windschitl, Exe, & Ubel, 2011). 
In another example, researchers found that rural mothers were more than twice as likely 
(45% vs. 20%) to comply with a nutritionist’s recommendation to administer cod-liver oil to 
infants when they received this recommendation in six-person discussion groups as opposed 
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to individual consultations (Bertrand, Mullainathan, & Shafir, 2006; Ross & Nisbett, 1991). 
Our normative intervention followed a similar rationale—to create a new norm for prostate 
cancer treatment decisions rather than attempt to isolate men from the expectations of their 
groups, which could range from friends and family to fellow patients to physicians.
In the context of decision making about management for clinically localized prostate cancer, 
normative behaviors are currently informed by conventional wisdom that a cancer diagnosis 
should be followed by immediate treatment and that delaying treatment puts the patient at 
greater risk of progression, need for more aggressive treatments, and perhaps death. We 
attempted to create messages that depict AS as a reasonable choice for men and to slow the 
decision-making process by communicating that patients have time to weigh their values 
and preferences and do not need to make a decision immediately. These messages took the 
form of quotations from men about the decision-making process. An example of a quotation 
about the non-acute nature of the decision follows: “Deciding about prostate cancer is a 
decision you make in weeks, not days.”
The goal of this study was to test the acceptability of normative messages about AS (in 
contrast to immediate treatment) as a management option for men with clinically localized 
prostate cancer from the perspectives of men who have made a treatment decision. This 
group of men was selected because they benefit from the experiences of going through the 
decision-making process, selecting a management option, and living with the consequences 
of their management decisions. We developed messages that might help men to consider AS 
as a reasonable option for managing prostate cancer and then tested these messages in a 
sample of men who had a previous diagnosis of early-stage prostate cancer.
Methods
A Framework for Evaluating the Acceptability of Normative Messages in Decision Making
The following framework for assessing the acceptability of a message about management 
options for localized prostate cancer (including AS) was adapted from similar studies of 
normative messages related to prevention of behaviors with adverse consequences such as 
disordered eating, cigarette smoking, and unhealthy weight loss dieting (Durkin, Paxton, & 
Wertheim, 2005; Flynn et al., 2007; Paxton, Wertheim, Pilawski, Durkin, & Holt, 2002). In 
this study, our normative messages support AS.
We suggest that an effective message about AS for men considering management options 
for localized prostate cancer should meet the following criteria:
1. The message should be perceived as credible, that is, “something a man would say” 
(believability).
2. The message should be perceived as providing accurate information (accuracy).
3. The message should be seen as important to men facing a decision about treatment 
(utility).
Within this framework it is possible to identify several problem areas or gaps in information 
needs that can be used to inform the design of effective messages. For a message to be 
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accepted, it must be believable to the target audience. Messages perceived as not believable 
will have little effect on decision making and may hurt the credibility of the overall 
educational materials. It would seem likely that a message perceived as believable would 
also be seen as accurate. However, if messages challenge widely held beliefs or reinforce 
misinformation, factual messages may be seen as less accurate or believable. Finally, 
messages may be seen as being more or less important in the decision. We anticipate that 
utility or importance should be less strongly related to the other two dimensions. As 
suggested, the joint examination of the three dimensions may reveal important gaps for the 
provision of messages. We have seen that there may be interesting juxtapositions of 
believability and accuracy that may suggest the need for message strategies to counteract 
misconceptions or to reinforce factually correct messages that are poorly accepted (viewed 
as not believable).
Additional criteria should be met for a message to be viewed as acceptable. Effective 
messages should not be affected by biases, that is, acceptability of the message should be 
invariant across characteristics of the men viewing it. In this case, ratings of acceptability of 
the message should not differ for younger and older men, for men who chose to be treated 
compared with those who chose observation, and across other factors such as marital status. 
Finally, ratings of the normative messages should be associated with overall attitudes about 
AS serving as a check of the validity of the messages.
Designing the Messages
Our approach to designing the messages was to select key themes reflecting men’s 
perceptions of AS from a variety of sources, identify a change objective related to the theme, 
and rate the messages based on how strongly they favored AS over immediate treatment. 
The goal was to have a series of messages, varying in the degree to which they favored AS 
or immediate treatment and representing different change objectives. A change objective is a 
statement of what must change so that a person may adopt a certain behavior such as active 
surveillance (Bartholomew, Parcel, Kok, Gottlieb, & Fernández, 2011). Examples are: “A 
man sees himself as having time to make a decision” and “A man recognizes that choosing 
AS may require additional explanation to others.” Each message was written as a quote 
along with a man’s name (fictitious identity) and identification of the source of the message 
as either a prostate cancer survivor (eight messages) or a surgeon (one message).
In designing messages about AS we used three primary sources of information: 1) personal 
interviews with men who were treated for prostate cancer or who chose AS, 2) review of the 
literature on treatment decision making in prostate cancer, and 3) other sources such as blogs 
and survivor websites. Personal interviews, the main source of messages, were conducted 
with prostate cancer patients 6–18 months after completing treatment or the decision to 
follow an AS protocol. Details of the methods and findings from the patient interviews can 
be found elsewhere (Volk et al., 2013). We began by abstracting quotes from the interviews 
or drafting quotes based on the literature review or survivor websites. With intervention 
development in mind, a performance objective associated with each message was assigned. 
From there, we identified redundant messages and reduced the number of candidate 
messages. Each message was then rated independently by three members of the research 
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team (JBB, TLB, RJV) for valence related to favoring AS. The final nine messages reflected 
key themes and performance objectives related to AS decisions and varied in the degree to 
which they favored AS or immediate treatment. The messages tested in this study and their 
sources can be found in Table 1.
Participants and Procedures for Rating the Messages
Participants for the study were recruited through prostate cancer support organizations over 
a period of four months (September 2012 to January 2013). Organizations were identified 
through Google and Facebook, as well as referrals from colleagues. Seven organizations 
(American Cancer Society Survivors’ Network, 50 Hoops, Malecare, Prostate.net, Prostate 
Cancer Research Institute, Urology Research and Education Foundation, and US Too) 
agreed to describe the survey and eligibility criteria to their members and provide them with 
a hyperlink to the study website using a variety of media (i.e., organizational newsletters, 
direct email, announcements on their websites). Organizations received a $25 contribution 
for every survey completed under their auspices.
Interested participants followed the hyperlink to an informed consent statement that ended 
with an invitation to give their assent by selecting the “I consent and agree to participate” 
option to begin the study. After participants consented, they answered several questions to 
assess eligibility. Eligible participants (able to read English, received diagnosis of prostate 
cancer 6 months to 5 years previously, cancer not spread beyond the gland at the time of 
diagnosis) then completed the web-based study survey. To minimize burden during data 
collection, participants were randomly assigned to receive only three of the nine messages. 
For each message, participants were asked the following questions: 1) Do you believe this is 
something a man (a doctor) would say? 2) Do you believe this statement is accurate? 3) 
How important is it that men with prostate cancer hear this statement when making a 
decision about treatment? Response options for questions 1 and 2 were “yes,” “no,” and 
“I’m not sure.” Response options for question 3 were “very important,” “somewhat 
important,” and “not important.” A fourth question was included to provide an indicator of 
the perceived effect of the message on men’s decisions about AS: What impact would this 
statement have on men deciding about prostate cancer treatment? For this question, response 
options were “men would be more likely to choose active surveillance,” “men would be 
more likely to choose immediate treatment,” and “the statement would have little or no 
impact on men’s decisions.” Participants were able to review and change their responses 
before submitting the survey. The study questionnaire was designed and maintained using 
the Qualtrics® survey software system. To prevent multiple entries from the same 
individual, parameters were set so that duplicate entries were not allowed from the same 
Internet Protocol (IP) address.
The protocol was approved by the Committee for the Protection of Human Subjects at The 
University of Texas Health Science Center at Houston and the Institutional Review Board at 
The University of Texas MD Anderson Cancer Center.
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Incomplete questionnaires were excluded from data analysis. The message ratings were 
tabulated and reported as percentages. We tested for bias of the messages by examining 
correlations of the message ratings with the participants’ age, treatment received (self-
reported receipt of AS or watchful waiting compared with all other treatments), and marital 
status. To test the validity of the normative messages, we examined correlations of each 
message with a broad measure of attitudes towards acceptability of AS developed for this 
study. The attitudes measure was adapted from a measure of perceived attributes of eHealth 
innovations (Atkinson, 2007). A positive correlation would indicate that acceptability of the 
message was associated with more favorable attitudes toward AS in general. Because of the 
large number of correlations, we used a Bonferroni adjustment of the type I error rate of 
0.05/36, or P < 0.0014.
Results
We followed the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) in 
reporting the methods and results of the study (Eysenbach, 2004). The study website was 
visited by 1,084 unique site visitors. Of those, 947 consented to study participation. 
Approximately 56% (n=533) of those who consented to participate did not meet eligibility 
criteria. Three hundred thirty-one of the 414 eligible participants who began the study 
completed the full questionnaire.
Characteristics of the Participants
The 331 respondents with completed questionnaires had an average age of 64.9 ± 8.4 years 
(range 45–96 years). Of the 331 respondents, 88% classified themselves as white, 82% were 
married, and 93% were college educated. Treatment history included surgery (37%), AS 
(24%), radiation (26%), and other (13%). Demographic characteristics of the included 
respondents are shown in Table 2.
Ratings of Normative Messages for Acceptability
For the believability dimension, ratings of messages largely ranged from 65.1% (message 4, 
representing trust in the AS protocol to catch any progression in time for curative treatment) 
to 90.1% (message 8, regret over not giving AS a second thought) (see Table 3). Message 9, 
a favorable quote about AS attributed to a surgeon, was a negative outlier on the 
believability dimension. Ratings of message accuracy varied more widely, with 35.8% 
(message 4) to 85.6% (message 1, having time to think about options) of respondents 
judging the various messages to be accurate. Men’s ratings of the utility of different 
messages ranged from 36.0% (message 9) to 82.9% (message 1). Again, message 4 about 
trusting the AS protocol fared poorly.
We also examined the ratings for the messages across the three dimensions, contrasting 
messages high on all dimensions with one that was low on the multiple dimensions. The 
message “you don’t have to panic…you have time to think about your options” (message 1) 
was perceived as believable, accurate, and important for men to hear by more than 80% of 
the respondents. Similarly, more than 75% of respondents rated as believable and accurate a 
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message about having low-risk prostate cancer and “not wanting to rush into getting 
something done right away,” (message 3) and 66% rated it very important for men to hear. 
In contrast, messages about trust in the AS protocol and “knowing in plenty of time” if 
treatment is needed (message 4) were rated as accurate by only about 35% of participants. 
Message 9, in which a surgeon describes men who chose AS as “jubilant” and “delighted” 
with their lack of side effects, received consistently low ratings in every dimension: 
believability, 13.5%; accuracy, 36.9%; utility, 36.0%.
Effect of Messages on Decision Making, Tests for Bias, and Validity
Perceptions of the impact of each message on men’s likelihood of choosing AS ranged from 
60.4% (message 1) to 77.3% (message 6, prolonging the decision until treatment options 
have improved) with one exception. The outlier was message 8 (regret over not giving AS a 
second thought), which was viewed as favoring an AS decision by 45.1% of respondents. 
About 1/3 of respondents reported that message 1, addressing time to think about the 
options, would have little or no effect on men’s treatment decisions. In our tests for bias of 
the messages, we found no evidence of any association with the man’s age, the treatment 
received, or marital status. Finally, seven of the nine messages were correlated with overall 
attitudes about the acceptability of AS, with messages 1 and 8 not being associated (see 
Table 3).
Discussion
This study evaluated the acceptability of normative messages about AS among men 
diagnosed with localized prostate cancer. Generally, participants gave higher ratings to 
messages about the slow progression of prostate cancer paired with the idea that an 
immediate decision was not necessary. Messages such as “You don’t need to panic” 
(message 1), “Prostate cancer is one of the slowest growing cancers of all” (message 2), and 
“It’s at such a low level, I’ve got a little time” (message 3) were highly rated in all three 
metrics.
Messages that more strongly favored AS, on the other hand, received mixed ratings. 
Messages that presented AS as a way of living normally “until I absolutely have to do 
something else” (message 5) or “until the treatment options have improved” (message 6) 
were perceived as highly believable but received only moderate accuracy and importance 
ratings. Messages that suggested that under AS men could “see if [cancer] spreads and 
then… make that decision” (message 7) and still “know in plenty of time” fared still worse. 
While these statements were plausible as something a man might say, they received low 
ratings on accuracy and importance for other men to hear, suggesting an underlying 
discomfort with not treating a cancer immediately.
The dichotomy between the evidence-based effectiveness of AS as a viable treatment 
strategy for low-risk prostate cancer (Wilt, 2012) and the societal bias in favor of radical 
treatment (Jacobs et al., 2013) creates the need for a new type of decision support 
intervention, including patient decision aids, that highlights AS as a reasonable option. 
Despite the challenges of supporting informed decision making for patients, their families, 
and their health care providers (including setting expectations for quality indicators), 
Volk et al. Page 7













decision aids can be a useful method for providing balanced information about choices. 
Using narratives in patient decision aids may be a powerful strategy for enhancing the 
acceptability of AS (Bekker, 2010; Shaffer & Zikmund-Fisher, 2013). This analysis of 
normative messages in relation to prostate cancer treatment options suggests that message 
themes that stress treatment as a decision that requires careful consideration rather than 
immediate action may be most helpful in nudging men with localized disease to consider 
AS. However, convincing men to wait and be assured that a cure is still possible is more 
difficult and is a task in which our normative messages fared poorly. Further intervention 
may be needed with these low-risk patients to modify their belief that cancer should always 
be addressed with immediate, aggressive treatment. Men must be assured that AS is a 
proactive treatment and educated that AS does not inherently signify waiting to treat or take 
action until the cancer has done irreparable damage.
Our results are consistent with those of the ProtecT prospective trial as reported by Donovan 
(Donovan, 2012). When consenting to randomization, potential participants in ProtecT were 
at first confused and frightened by the apparent passivity of what was at first termed 
“watchful waiting.” However, after the treatment option was renamed “active monitoring” 
and presented with greater clarity and with enthusiasm equal to that shown for the other 
treatment options, agreement to randomization rose from 40% to 70%, signifying greater 
acceptance for active monitoring. Patients in the ProtecT trial, like those in our study, were 
similarly disinclined to accept waiting rather than undergoing immediate curative treatment, 
but after their fears and doubts about delaying radical treatment were assuaged they accepted 
AS more readily.
This study has several limitations. Men in this study were highly educated and most were 
Caucasian. The participants were members of online support groups and may have had a 
greater interest in treatment decision making about prostate cancer than other men. Finally, 
we chose prostate cancer survivors for this study. These men benefit for the experience and 
knowledge gained in going through the decision making process about management of their 
diagnosis. We do not know how men facing a decision about management would rate the 
messages.
Inclusion of normative messages in decision aids is controversial largely because when 
making healthcare decisions, patients tend to give greater consideration to information in a 
narrative format than information in a statistical format (Shaffer & Zikmund-Fisher, 2013). 
Thus, decision aids including these messages have the potential for imbalance in favor of 
AS. However, the existing bias against AS should also be considered. Patients may fear that 
any delay in even unnecessary treatment will negatively affect health outcomes, and 
physicians may prefer to treat with the potential for cure rather than promote AS as an 
equally appropriate option in low-risk cancer (Jacobs et al., 2013). Therefore, quality 
decision aids may use narrative framing ethically to promote AS and truly balance the 
informed decision-making process by affording this strategy due consideration (Blumenthal-
Barby, Cantor, Russell, Naik, & Volk, 2013). Normative messages may be a viable method 
to facilitate informed decision making with respect to AS for men, their families, and their 
medical providers. Further, they might help right the larger imbalance toward overtreatment 
for other cancer diagnoses.
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Table 1
Normative messages about active surveillance (AS) for localized prostate cancer tested in the study.
Normative Message Theme (change objective) Source of message*
1. “A diagnosis 
of cancer is 
frightening, 
but you don’t 
need to panic. 
You have 
time to think 
about your 
options.”
Sees himself as having 
time to make a decision.
Interviews with treated and AS prostate cancer patients.
2. “Prostate 
cancer is one 
of the slowest 
growing 
cancers of all 





Sees prostate cancer as 
often slow growing.
Commonly cited quote about non-aggressiveness of some prostate cancers.
3. “…but I just 
felt like it’s at 
such a low 
level, I’ve got 
a little time on 
my side. I just 






Understands that there is a 
spectrum of risk for 
localized prostate cancer 
and knows where he falls 
on that continuum.
Interviews with treated and AS prostate cancer patients.
4. “Well, I just 
think they’re 
sufficiently on 






in plenty of 
time.”
Trusts the AS protocol 
would catch disease 
progression in time.
Interviews with treated and AS prostate cancer patients.
5. “With active 
surveillance, 
my life goes 






that until I 
absolutely 
have to do 
something 
else.”
Recognizes the potential 
burden (includes 
likelihood) of adverse 
effects (e.g., urinary 
incontinence, impotence) 
from active treatment (e.g., 
surgery, radiation).
Interviews with treated and AS prostate cancer patients.
6. “…as long as 
I’m keeping a 
close eye on it 
with my 
doctors, I can 
possibly 
prolong this 
for a number 
of years until 
Regards active 
surveillance as a reversible 
decision.
Interviews with treated and AS prostate cancer patients.
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7. “It depends on 
your age. If 
you’re young 
and you have 
a sexual life, I 
would 
definitely wait 
and just watch 
and see if it 
spreads, and 
then you can 
always make 
that decision, 
but I just 
wouldn’t 
jump into it.”
Sees AS as a decision that 
varies by characteristics of 
the man.
Interviews with treated and AS prostate cancer patients.









options. I was 
from the old 
school of 
thinking that 
says, “If it’s 
cancer, I want 
it out!”
Recognizes that some men 
want immediate treatment.
Adapted from http://www.healthboards.com/boards/cancer-prostate/541701-active-surveillance.html




after being on 
AS for a few 
years. They 








had not gone 
that route.”
Understands that doctors 
recognize that men may 
want to avoid treatment 
side effects.
Adapted from an interview with a doctor, http://www.healingwell.com/community/default.aspx?
f=35&m=2358857&p=5
Messages 1–8 are from the perspective of a prostate cancer survivor. Message 9 is from the perspective of a doctor/surgeon.
*
Interviews with prostate cancer patients who received immediate treatment (n = 15) or selected active surveillance (n = 15) were completed by the 
research team and served as the source for several quotes.
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Table 2
Sociodemographic characteristics of the 331 men with localized prostate cancer.
Characteristic No. %
Age, years (mean) 64.94 —
Education
 High school graduate or less 19 5.7
 Some college or college graduate 163 49.2
 Postgraduate 146 44.1
 Not stated 3 0.9
Ethnicity
 White, non-Hispanic 291 87.9
 Other 37 11.2
 Not stated 3 0.9
Relationship status
 Married 271 81.9
 Unmarried 57 17.2
 Not stated 3 0.9
Treatments received
 Surgery (laparoscopic) 12 3.6
 Surgery (robotic) 110 33.2
 External beam radiation therapy 86 26.0
 Brachytherapy 20 6.0
 Active surveillance 79 23.9
 Other 11 3.3
 None 13 3.9
All percentages may not add to 100% due to rounding.
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